Is CureVac NV Stock a Good Investment?
CureVac NV Investment Advice | CVAC |
- Examine CureVac NV's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research CureVac NV's leadership team and their track record. Good management can help CureVac NV navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact CureVac NV's business and its evolving consumer preferences.
- Compare CureVac NV's performance and market position to its competitors. Analyze how CureVac NV is positioned in terms of product offerings, innovation, and market share.
- Check if CureVac NV pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about CureVac NV's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in CureVac NV stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if CureVac NV is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine CureVac NV Stock
Researching CureVac NV's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.85. Some equities with similar Price to Book (P/B) outperform the market in the long run. CureVac NV has Price/Earnings To Growth (PEG) ratio of 0.07. The entity had not issued any dividends in recent years.
To determine if CureVac NV is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CureVac NV's research are outlined below:
| CureVac NV generated a negative expected return over the last 90 days | |
| CureVac NV has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 53.76 M. Net Loss for the year was (260.17 M) with loss before overhead, payroll, taxes, and interest of (91.55 M). | |
| CureVac NV currently holds about 540.87 M in cash with (267.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85. | |
| Roughly 45.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Analysts Are Optimistic Well See A Profit From CureVac N.V. |
CureVac NV Quarterly Liabilities And Stockholders Equity |
|
CureVac NV uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CureVac NV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CureVac NV's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 23rd of April 2024 Upcoming Quarterly Report | View | |
| 4th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 23rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact CureVac NV's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises CureVac NV's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-18 | 2022-06-30 | -0.26 | -0.31 | -0.05 | 19 | ||
2023-08-17 | 2023-06-30 | -0.24 | -0.3 | -0.06 | 25 | ||
2023-05-30 | 2023-03-31 | -0.34 | -0.27 | 0.07 | 20 | ||
2024-08-15 | 2024-06-30 | -0.26 | -0.3482 | -0.0882 | 33 | ||
2020-11-30 | 2020-09-30 | -0.35 | -0.24 | 0.11 | 31 | ||
2021-04-15 | 2021-03-31 | -0.51 | -0.33 | 0.18 | 35 | ||
2024-04-25 | 2024-03-31 | -0.18 | -0.39 | -0.21 | 116 | ||
2024-03-12 | 2023-12-31 | -0.2 | -0.42 | -0.22 | 110 |
CureVac NV Target Price Consensus
CureVac target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. CureVac NV's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Buy |
Most CureVac analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand CureVac stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of CureVac NV, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCureVac NV Target Price Projection
CureVac NV's current and average target prices are 2.87 and 14.91, respectively. The current price of CureVac NV is the price at which CureVac NV is currently trading. On the other hand, CureVac NV's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
CureVac NV Market Quote on 29th of November 2024
Target Price
Analyst Consensus On CureVac NV Target Price
CureVac NV Analyst Ratings
CureVac NV's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about CureVac NV stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of CureVac NV's financials, market performance, and future outlook by experienced professionals. CureVac NV's historical ratings below, therefore, can serve as a valuable tool for investors.Know CureVac NV's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CureVac NV is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CureVac NV backward and forwards among themselves. CureVac NV's institutional investor refers to the entity that pools money to purchase CureVac NV's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Swiss National Bank | 2024-09-30 | 198.5 K | Walleye Trading Advisors, Llc | 2024-06-30 | 187.9 K | Deutsche Bank Ag | 2024-06-30 | 151 K | Susquehanna International Group, Llp | 2024-06-30 | 150.6 K | Freestone Capital Holdings, Llc | 2024-06-30 | 139.6 K | Legal & General Group Plc | 2024-06-30 | 119 K | Boothbay Fund Management, Llc | 2024-09-30 | 113.2 K | Ubs Group Ag | 2024-06-30 | 113 K | Norges Bank | 2024-06-30 | 110.9 K | Millennium Management Llc | 2024-06-30 | 2.9 M | Blackrock Inc | 2024-06-30 | 2.3 M |
CureVac NV's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 643.85 M.Market Cap |
|
CureVac NV's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.50) | (0.53) |
Determining CureVac NV's profitability involves analyzing its financial statements and using various financial metrics to determine if CureVac NV is a good buy. For example, gross profit margin measures CureVac NV's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CureVac NV's profitability and make more informed investment decisions.
Please note, the presentation of CureVac NV's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CureVac NV's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CureVac NV's management manipulating its earnings.
Evaluate CureVac NV's management efficiency
CureVac NV has return on total asset (ROA) of (0.2452) % which means that it has lost $0.2452 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.543) %, meaning that it created substantial loss on money invested by shareholders. CureVac NV's management efficiency ratios could be used to measure how well CureVac NV manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, CureVac NV's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 645.8 M, whereas Net Tangible Assets are forecasted to decline to about 407.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.34 | 1.90 | |
| Tangible Book Value Per Share | 2.22 | 1.82 | |
| Enterprise Value Over EBITDA | (2.05) | (2.15) | |
| Price Book Value Ratio | 1.62 | 1.54 | |
| Enterprise Value Multiple | (2.05) | (2.15) | |
| Price Fair Value | 1.62 | 1.54 | |
| Enterprise Value | 479.1 M | 455.2 M |
Evaluating the management effectiveness of CureVac NV allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The CureVac Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 2.611 |
Basic technical analysis of CureVac Stock
As of the 29th of November, CureVac NV shows the Risk Adjusted Performance of (0.03), standard deviation of 3.19, and Mean Deviation of 2.37. CureVac NV technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.CureVac NV's Outstanding Corporate Bonds
CureVac NV issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CureVac NV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CureVac bonds can be classified according to their maturity, which is the date when CureVac NV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand CureVac NV's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing CureVac NV's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 2.37 | |||
| Coefficient Of Variation | (2,093) | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.2 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 16.27 | |||
| Value At Risk | (4.51) | |||
| Potential Upside | 4.74 | |||
| Skewness | 0.8393 | |||
| Kurtosis | 2.21 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 2.37 | |||
| Coefficient Of Variation | (2,093) | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.2 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 16.27 | |||
| Value At Risk | (4.51) | |||
| Potential Upside | 4.74 | |||
| Skewness | 0.8393 | |||
| Kurtosis | 2.21 |
Consider CureVac NV's intraday indicators
CureVac NV intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CureVac NV stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CureVac NV Corporate Filings
6K | 12th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 25th of April 2024 Other Reports | ViewVerify | |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
CureVac Stock media impact
Far too much social signal, news, headlines, and media speculation about CureVac NV that are available to investors today. That information is available publicly through CureVac media outlets and privately through word of mouth or via CureVac internal channels. However, regardless of the origin, that massive amount of CureVac data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CureVac NV news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CureVac NV relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CureVac NV's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CureVac NV alpha.
CureVac NV Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards CureVac NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
CureVac NV Corporate Management
| Pierre BSc | CFO MD | Profile | |
| Patrick Baumhof | Senior Technology | Profile | |
| AxelSven Malkomes | Chief Officer | Profile | |
| Ronald Plasterk | Senior Innovation | Profile | |
| Igor MSc | Chief Board | Profile | |
| Antony Blanc | Chief MD | Profile | |
| Sarah Fakih | Vice Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.49 | Revenue Per Share 0.294 | Quarterly Revenue Growth 0.905 | Return On Assets (0.25) | Return On Equity (0.54) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between CureVac NV's value and its price, as these two are different measures arrived at by various means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.